980
Participants
Start Date
November 18, 2024
Primary Completion Date
April 3, 2026
Study Completion Date
April 3, 2026
RIV (recombinant influenza vaccine)
Influenza, inactivated, split virus or surface antigen
rC19 (dose 1)
Protein subunit
RIV + rC19 (dose 1)
RIV component: Influenza, inactivated, split virus or surface antigen NVXC19 component: Protein subunit
RIV + rC19 (dose 2)
RIV component: Influenza, inactivated, split virus or surface antigen NVXC19 component: Protein subunit
RIV + rC19 (dose 3)
RIV component: Influenza, inactivated, split virus or surface antigen NVXC19 component: Protein subunit
RIV + rC19 (dose 4)
RIV component: Influenza, inactivated, split virus or surface antigen NVXC19 component: Protein subunit
Placebo (0.9% NaCl)
Normal saline
Synexus Clinical Research US - Anderson- Site Number : 8400001, Anderson
Synexus Clinical Research US - Orlando- Site Number : 8400007, Orlando
Optimal Research - Florida- Site Number : 8400006, Melbourne
Synexus Clinical Research US - Cincinnati- Site Number : 8400003, Cincinnati
Synexus Clinical Research US - Evansville- Site Number : 8400004, Evansville
Synexus Clinical Research US - Minneapolis- Site Number : 8400011, Richfield
Optimal Research - Illinois- Site Number : 8400008, Peoria
Central Phoenix Medical Clinic- Site Number : 8400009, Phoenix
Synexus-Las Vegas- Site Number : 8400005, Las Vegas
Synexus Clinical Research US, Inc. - Cerritos- Site Number : 8400002, Cerritos
Synexus Clinical Research US - Vista- Site Number : 8400010, Vista
Walgreens Clinical Trials-Malden- Site Number : 8400012, Malden
Lead Sponsor
Sanofi
INDUSTRY